{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-103787","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.851997+00:00","generated_at":"2026-06-17T01:24:11.367071+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Intellia appoints Bill Chase to board; Caroline Dorsa to retire June 15, 2023","bullets":["Bill Chase, former AbbVie CFO, appointed as Class III director, effective April 14, 2023.","Caroline Dorsa to retire from board on June 15, 2023, after being appointed chair of Biogen's board.","Chase will serve on audit committee and succeed Dorsa as audit committee chair.","Chase received grant of 14,931 stock options and 10,483 RSUs under director compensation program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-103787","json":"https://secwatch.observer/filing/0001193125-23-103787.json","markdown":"https://secwatch.observer/filing/0001193125-23-103787.md","text":"https://secwatch.observer/filing/0001193125-23-103787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/0001193125-23-103787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/d485270d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:24:11.367071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"733f829ea7","claim":"Bill Chase was appointed as Class III Director at Intellia Therapeutics, Inc..","evidence_excerpt":"the Board appointed Bill Chase, M.B.A., as a Class III director, with a term expiring at the 2025 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/0001193125-23-103787-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}